Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   Dezheng Huo   and   Olatoyosi Odenike.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.411
         
        
        
     
 
    
        
        - 
            A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
            
            
                Score: 0.234
            
         
        
        - 
            Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008 Nov 01; 14(21):7095-101.
            
            
                Score: 0.077
            
         
        
        - 
            A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
            
            
                Score: 0.058
            
         
        
        - 
            High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
            
            
                Score: 0.024
            
         
        
        - 
            Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
            
            
                Score: 0.018